Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vomiting blood

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    258 result(s) found for: Vomiting blood. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005700-15 Sponsor Protocol Number: marha1983 Start Date*: 2013-01-07
    Sponsor Name:Lennart Svensson Linköping University Medical Faculty
    Full Title: Can 5-HT3 receptor antagonists be used to limit vomiting in rota- and norovirus infections?
    Medical condition: Virus caused vomiting and effect of the antiemetic drug Ondansetron
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000370-31 Sponsor Protocol Number: NKT102260 Start Date*: 2005-05-20
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Ant...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000651-16 Sponsor Protocol Number: 0869-208 Start Date*: 2011-07-20
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention...
    Medical condition: Pediatric Chemotherapy induced nausea and vomiting (CINV)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10052401 Vomiting post chemotherapy LLT
    13.1 10017947 - Gastrointestinal disorders 10056989 Nausea post chemotherapy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) PT (Not Authorised) LT (Completed) ES (Completed) NL (Completed) DK (Completed) HU (Completed) SI (Completed) GR (Completed) GB (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-007770-37 Sponsor Protocol Number: DP10002 Start Date*: 2009-05-29
    Sponsor Name:Acacia Pharma Ltd.
    Full Title: Randomised, double-blind, placebo-controlled, Phase II study to assess the safety and efficacy of different doses of intravenous APD405 (buspirone for IV injection) for the prevention of post-opera...
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000778-46 Sponsor Protocol Number: LiBiDi-EK314/11 Start Date*: 2013-01-17
    Sponsor Name:Forschungszentrum Jülich GmbH
    Full Title: Elucidation of Lithium Working Mechanism in Bipolar Disorder by means of Multi Modal Brain Imaging (LiBiDi)
    Medical condition: Healthy volunteers Bipolar patients type 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10043890 Tiredness LLT
    14.1 10017947 - Gastrointestinal disorders 10028821 Nausea with vomiting LLT
    14.1 10029205 - Nervous system disorders 10013575 Dizziness and giddiness LLT
    14.1 10029205 - Nervous system disorders 10051385 Drug-induced headache LLT
    14.1 10018065 - General disorders and administration site conditions 10021689 Increased thirst LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036164 Poor weight gain LLT
    14.1 10029205 - Nervous system disorders 10044577 Tremor of hands LLT
    14.1 10029205 - Nervous system disorders 10027176 Memory loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004267-71 Sponsor Protocol Number: DP10006 Start Date*: 2011-12-12
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled, dose-ranging Phase II study of APD421 (amisulpride for IV injection) for the prevention of post-operative nausea and vomiting
    Medical condition: Post-operative nausea and vomiting (PONV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000663-80 Sponsor Protocol Number: ONO-7847-03 Start Date*: 2018-02-16
    Sponsor Name:Ono Pharmaceutical Co., Ltd.
    Full Title: ONO-7847 Japanese Clinical Study in Pediatric Patients Multicenter, open-label, uncontrolled study for the prevention of CINV
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005623-27 Sponsor Protocol Number: RM-131-009 Start Date*: 2015-04-08
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastropa...
    Medical condition: Vomiting symptoms in patient with moderate to severe diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001021-22 Sponsor Protocol Number: NKO101287 Start Date*: 2005-02-08
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 m...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001944-21 Sponsor Protocol Number: PALO-03-14 Start Date*: 2005-09-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting ...
    Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022170-14 Sponsor Protocol Number: DN10007 Start Date*: 2010-12-16
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting
    Medical condition: Cisplatin-induced nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003992-30 Sponsor Protocol Number: DP10019 Start Date*: 2016-03-08
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had prior prophylaxis
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002041-59 Sponsor Protocol Number: DP10018 Start Date*: 2015-09-11
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had no prior prophyl...
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002177-20 Sponsor Protocol Number: RLM-MD-02 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002144-33 Sponsor Protocol Number: RLM-MD-04 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) BG (Prematurely Ended) DK (Completed) AT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000369-37 Sponsor Protocol Number: NKT102245 Start Date*: 2005-02-01
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjun...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002136-16 Sponsor Protocol Number: RLM-MD-01 Start Date*: 2019-04-02
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016775-30 Sponsor Protocol Number: NETU-08-18 Start Date*: 2011-02-24
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron ...
    Medical condition: Nausea and vomiting in cancer patients receiving moderately emetogenic theraphy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000857-10 Sponsor Protocol Number: NA Start Date*: 2022-05-16
    Sponsor Name:CHU de Liège
    Full Title: Isobaric versus hyperbaric intrathecal bupivacaine: influence of baricity on blood pression variation during elective total knee arthroplasty: a randomized clinical trial.
    Medical condition: Total knee arthroplasty
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001027-33 Sponsor Protocol Number: PAFIBAR1.0 Start Date*: 2023-06-07
    Sponsor Name:FIMABIS
    Full Title: Evaluation of the effect of Opioid-Free Anesthesia on oxygenation in bariatric surgery
    Medical condition: Bariatric surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10068900 Bariatric surgery LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 09:37:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA